KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS).

Donel M Martin, Anna J Harvey, Bernard Baune, Michael Berk, Gregory L Carter, Vanessa Dong, Nick Glozier, Paul Glue, Sean Hood, Dusan Hadzi-Pavlovic, Maree Hackett, Natalie Mills, Shanthi Sarma, Andrew Somogyi, Anthony Rodgers, Colleen K Loo

J Affect Disord 352 163-170

PMID38378088
PMCID-
DOI10.1016/j.jad.2024.02.052
发表日期2024-02-20
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Due to its rapid antidepressant effect, ketamine has recently been clinically translated for people with treatment-resistant depression. However, its cognitive profile remains unclear, particularly with repeated and higher doses. In the present study, we report the cognitive results from a recent large multicentre randomised controlled trial, the Ketamine for Adult Depression Study (KADS). METHODS: In this randomised, double-blind, active-controlled, parallel group, multicentre phase 3 trial study we investigated potential cognitive changes following repeated treatment of subcutaneous racemic ketamine compared to an active comparator, midazolam, over 4 weeks, which involved two cohorts; Cohort 1 involved a fixed dose treatment protocol (0.5 mg/kg ketamine), Cohort 2 involved a dose escalation protocol (0.5-0.9 mg/kg) based on mood outcomes. Participants with treatment-resistant Major Depressive Disorder (MDD) were recruited from 7 mood disorder centres and were randomly assigned to receive ketamine (Cohort 1 n = 33; Cohort 2 n = 53) or midazolam (Cohort 1 n = 35; Cohort 2 n = 53) in a 1:1 ratio. Cognitive measurements were assessed at baseline and at the end of randomised treatment. RESULTS: Results showed that in Cohort 1, there were no differences between ketamine and midazolam in cognitive outcomes. For Cohort 2, there was similarly no difference between conditions for cognitive outcomes. LIMITATIONS: The study included two Cohorts with different dosing regimes. CONCLUSIONS: The findings support the cognitive safety of repeated fixed and escalating doses at least in the short-term in people with treatment resistant MDD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。